崑崙萬維(300418.SZ)參投公司Cytek Biosciences在納斯達克上市
格隆匯7月25日丨崑崙萬維(300418.SZ)公佈,2020年10月,公司全資子公司Kunlun Tech Limited出資1,999,994.4美元投資Cytek Biosciences,Inc.。2021年7月23日,Cytek在美國納斯達克全球精選(Nasdaq GlobalSelect Market)成功上市,股票代碼“CTKB.O”,Cytek上市後公司持有Cytek普通股295,867股。
根據其招股説明書,Cytek是一家領先的細胞分析解決方案公司,通過創新的技術方法來推進實現下一代細胞分析工具。Cytek的核心產品,極光(Aurora)和北極光系統(Northern Lights systems),是領先的全光譜流式細胞儀,利用多個激光器的熒光特徵全光譜來區分單個細胞上的熒光標記(全光譜分析技術,簡稱“FSP”),能夠提供高分辨率,高含量和高靈敏度的細胞分析。Cytek的FSP技術平台包括儀器、試劑、軟件和服務,為客户提供全面、集成的整套解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.